CryoLogyx Nominated Innovation AveNEW and Compete for Ignite Award

Complete the form below to unlock access to ALL audio articles.
CryoLogyx LTD., a startup that specialises in cryopreserved cells and cryopreservation technology based in Coventry, United Kingdom, has been named a finalist competing for Ignite Award at SLAS2025 International Conference & Exhibition in San Diego. Building on their success as the winner of the New Product Award at SLAS2024 Europe in Barcelona, the company continues to demonstrate remarkable progress in innovation and product differentiation, earning them this global recognition.
CEO and co-founder, Dr Tom Congdon said: “We are excited and proud to be selected as an Innovation AveNEW company and finalist of Ignite Award. Our technology ensures that biologics maintain their quality and integrity, allowing researchers to start their experiments without spending time on culturing cells. At SLAS2025, we are excited to present how our solutions make life sciences research faster, better and simpler, while also collaborating with leaders in the industry.”
Want more breaking news?
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.
Subscribe for FREEThe current standard of cell culture involves manual or semi-automated processes to prepare cells for assays, which can be time-consuming, prone to variability, and often require extensive labour and expertise. Therefore, this traditional approach no longer meets the growing demand for speed and efficiency in high-throughput screening and other automated lab processes.
Existing cryoprotectants, such as DMSO, cannot prevent the damage caused by intracellular ice formation and propagation from cell-to-cell contacts.
CryoLogyx’s patented formulation, CryoShield™, addresses the challenges of traditional cryopreservation methods by integrating nature-inspired soluble ice nucleators, which are easily removed post-thaw, to control ice nucleation and mitigate supercooling effects. Using CryoShield™, cells adhered to microplates remain stable at -80°C for months and can be thawed with standard cell culture media, ready for assays 24 hours post-thaw. Not only is the recovery rate with CryoShield™ comparable to freshly cultured cells, but cell functions such as metabolic activity, proliferative capacity, and specific hepatic functions are also maintained.
Recognising the potential of this technology, CryoLogyx launched PlateReady™, its signature assay ready cells, which in practice require extensive handling, centrifugation, and pipetting. With CryoLogyx’s innovation, cells are provided in the assay ready format, allowing for minimal manipulation and are ready-to-use whenever users need them. This advancement means that cell culture users can spend more time collecting data instead of spending weeks preparing and culturing cells. The assay ready cells offered by the company are designed for immediate use, speeding up the drug discovery and target validation process. Additionally, this technology has the potential to reduce single-use plastic up to 86% at the point of use and enable broader access to cell models without advanced training. The applications of CryoShield™ have been expanded to include many sensitive cell types and even spheroids.
To compete with other strong finalists, Dr Tom Congdon will be presenting on the topic of Faster, Better, Simpler: Advanced Cryopreservation for Assay Ready Biologics to Streamline High-Throughput Screening during the 2:00 to 3:00 PM (local time) Ignite session on Monday, January 27th. He will be sharing informative data demonstrating the superior performance of their innovative solutions across diverse applications.